Utility of Genomic Platforms in Treatment Decisions in Axilla-Positive Breast Cancer.
Genomic platforms, Treatment decisions, Prognostic tool
Luminal breast cancer
Node positive
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
23
03
2022
revised:
12
07
2022
accepted:
24
07
2022
pubmed:
25
8
2022
medline:
28
9
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
Genomic platforms have proven to be more accurate as a prognostic tool than immunohistochemistry studies in patients with early, hormone receptor positive, HER 2 negative breast cancer and, in some cases, have also demonstrated predictive ability for chemotherapy benefit. They are now widely applied in node-negative disease, but their use in node-positive disease is more recent and more controversial, especially in premenopausal patients. In this article, we review the use of these tests in node-positive disease.
Identifiants
pubmed: 36002343
pii: S1526-8209(22)00176-8
doi: 10.1016/j.clbc.2022.07.014
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
634-641Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.